A comprehensive development strategy in buccal drug delivery.
This work combines several methods in an integrated strategy to develop a matrix for buccal administration. For this purpose, tablets containing selected mucoadhesive polymers loaded with a model drug (omeprazole), free or in a complexed form with cyclodextrins, and in the absence and presence of alkali agents were subjected to a battery of tests. Mucoadhesion studies, including simple factorial analysis, in vitro release studies with both model-dependent and model-independent analysis, and permeation studies were performed. Mucoadhesive profiles indicated that the presence of the drug decreases the mucoadhesion profile, probably due its hydrophobic character. In tablets loaded with the drug complexed with β-cyclodextrin or methyl-β-cyclodextrin, better results were obtained with the methylated derivative. This effect was attributed to the fact that in the case of β-cyclodextrin, more hydroxyl groups are available to interact with the mucoadhesive polymers, thus decreasing the mucoadhesion performance. The same result was observed in presence of the alkali agent (L: -arginine), in this case due to the excessive hydrophilic character of L: -arginine. Drug release from tablets was also evaluated, and results suggested that the dissolution profile with best characteristics was observed in the matrix loaded with omeprazole complexed with methyl-β-cyclodextrin in the presence of L: -arginine. Several mathematical models were applied to the dissolution curves, indicating that the release of the drug, in free or in complexed state, from the mucoadhesive matrices followed a super case II transport, as established on the basis of the Korsmeyer-Peppas function. The feasibility of drug buccal administration was assessed by permeation experiments on porcine buccal mucosa. The amount of drug permeated from mucoadhesive tablets presented a maximum value for the system containing drug complexed with the methylated cyclodextrin derivative in presence of L: -arginine. According to these results, the system containing the selected polymer mixture and the drug complexed with methyl-β-cyclodextrin in presence of L: -arginine showed a great potential as a buccal drug delivery formulation, in which a good compromise among mucoadhesion, dissolution, and permeation properties was achieved.
CICS, Centro de Investigação em Ciências da Saúde, Faculdade de Ciências da Saúde, Universidade da Beira Interior, Covilhã, Portugal. rfigueiras@fcsaude.ubi.pt
Ana
A
Figueiras
Alberto A C C
AA
Pais
Francisco J B
FJ
Veiga
D000269:Adhesives; D000278:Administration, Buccal; D000468:Alkalies / Q000737:chemistry; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000737:chemistry; D001120:Arginine / Q000737:chemistry; D002610:Cheek; D003505:Cyclodextrins / Q000032:analysis / Q000737:chemistry*; D004339:Drug Compounding / Q000379:methods*; D016503:Drug Delivery Systems; D005079:Excipients / Q000737:chemistry; D020100:Hydrogels; D009061:Mouth Mucosa; D009853:Omeprazole / Q000008:administration & dosage* / Q000737:chemistry; D011108:Polymers; D012995:Solubility; D013607:Tablets; D047392:beta-Cyclodextrins / Q000032:analysis / Q000737:chemistry*
D000269:Adhesives; D000468:Alkalies; D000897:Anti-Ulcer Agents; D003505:Cyclodextrins; D005079:Excipients; D020100:Hydrogels; D011108:Polymers; D013607:Tablets; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin; D001120:Arginine; C031215:betadex; D009853:Omeprazole